Related Experiment Video
Updated: May 15, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic viruses targeting CD47: a new road to success?
Chris H Takimoto1, Michael J Wick2
1START, San Antonio, Texas, USA chris.takimoto@startresearch.com.
Abstract:
Clinical success in the therapeutic targeting of the CD47 signaling pathway has thus far remained elusive despite a promising scientific rationale. Use of oncolytic viruses to deliver CD47 targeting agents represents a novel approach to modulate the immunological landscape of the tumor microenvironment and to generate a systemic antitumor immune response. In recent preclinical studies, an oncolytic herpes simplex virus-1 engineered to express an inhibitory CD47-binding nanobody demonstrated promising antitumor activity. Several other oncolytic viruses engineered to express CD47 inhibitory molecules are also in preclinical development. Oncolytic viruses have the potential to mitigate drug delivery issues and may avoid systemic toxicities that have limited conventional CD47 targeting therapeutics. These novel therapeutics warrant further evaluation in clinical trials. The potential advantages, limitations, and remaining critical questions regarding this strategic approach are discussed here.
Insights
Oncolytic viruses engineered to target CD47 show promise for cancer therapy. This novel approach may overcome limitations of current CD47-targeting drugs, warranting further clinical investigation.
Area of Science:
- Immunology
- Oncolytic Virology
- Cancer Therapeutics
Background:
- Therapeutic targeting of the CD47 signaling pathway has shown limited clinical success.
- CD47 acts as a "don't eat me" signal, protecting cancer cells from immune destruction.
Purpose of the Study:
- To explore the use of oncolytic viruses for delivering CD47-targeting agents.
- To evaluate the potential of oncolytic viruses to overcome challenges in CD47-based cancer therapy.
Main Methods:
- Engineering oncolytic viruses (e.g., herpes simplex virus-1) to express CD47-binding agents like nanobodies.
- Preclinical evaluation of engineered oncolytic viruses in tumor models.
Main Results:
- Preclinical studies demonstrate promising antitumor activity with engineered oncolytic viruses.
- Oncolytic viruses show potential to modulate the tumor microenvironment and enhance immune response.
Conclusions:
- Oncolytic viruses offer a novel strategy for CD47-targeted cancer therapy.
- This approach may mitigate drug delivery issues and reduce systemic toxicities associated with conventional CD47 therapeutics.
- Further clinical evaluation of oncolytic virus-based CD47 therapies is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...